DevazepideA potent CCK (cholecystokinin) inhibitor

Devazepide (CAS 103420-77-5)

Devazepide | CAS 103420-77-5 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_17, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203562, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 106ms
  • REVIEWS, PRODUCT
Synonym: MK 329
Application: A potent CCK (cholecystokinin) inhibitor
CAS Number: 103420-77-5
Purity: ≥98%
Molecular Weight: 408.46
Molecular Formula: C25H20N4O2
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Devazepide is a non-peptide CCK (cholecystokinin) receptor antagonist. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Studies indicate that Devazepide induces apoptosis in Ewing tumor growth studies, and does not reverse the blocking affect of IL-1β in rat studies. In addition, Devazepide has been reported to inhibit the growth of HT29-S-B6 cells and affect the cells morphology.


References

1. Miklautz, H. and Riemann, J. 1975. Arch. Pharm. 308: 760-768. PMID: 1200792
2. Forgue-Lafitte, M.E., et al. 1996. C. R. Acad. Sci. III. 319: 1133-1138. PMID: 9091185
3. Butera, P.C., et al. 2004. Physiol. Behav. 82: 777-783. PMID: 15451641
4. Carrillo, J., et al. 2009. Anticancer Drugs. 20: 527-533. PMID: 19407653

Physical State :
Solid
Solubility :
Soluble in DMSO (100 mM), and ethanol (50 mM).
Storage :
Store at 4° C
Melting Point :
299.97° C (Predicted)
Boiling Point :
~758.6° C at 760 mmHg (Predicted)
Density :
~1.3 g/cm3 (Predicted)
Refractive Index :
n20D 1.70 (Predicted)
Optical Activity :
α20/D -102°, c = 0.9 in chloroform
IC50 :
CCK-AR: IC50 = 0.08 nM (rat); CCK-AR: IC50 = 0.08 nM (human)
Ki Data :
CCK-AR: Ki= 0.16 nM (human); CCK-BR: Ki= 62 nM (human)
pK Values :
pKa: 13.25 (Predicted), pKb: 3.18 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
NL5994460
PubChem CID :
443375
MDL Number :
MFCD00864500
SMILES :
CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 64ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Carrillo et al Carrillo et al. (PubMed ID 19407653) found that devazepide induced apoptosis of Ewing tumor cells via CCK1-R antagonism. -SCBT Publication Review
Date published: 2015-02-08
  • y_2019, m_9, d_17, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203562, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 23ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.